Products are for professional/laboratory use only.
Being the third¹ liquid biopsy test for Biocartis, the Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay (Research Use Only), also marks an important milestone in the partnership with the leading science and technology company Merck².
Products are for professional/laboratory use only.
The Idylla™ ctKRAS Mutation Assay (Research Use Only, RUO), was developed in partnership with the leading science and technology company Merck1 on Biocartis’ molecular diagnostics platform Idylla™.
Introducing Biocartis Idylla – BRAF molecular results in as little as 90 minutes.
About 50 percent of all melanomas harbor mutations in the BRAF oncogene. Idylla™ BRAF Mutation Test detects BRAF mutations directly from FFPE tissue sections in 90 minutes with less than 2 minutes hands-on time.